ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "9a4a6795-b625-47e1-9b79-58d73108c3d4"}, "_deposit": {"id": "8221", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "8221"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00008221", "sets": ["456", "884"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Current Trends and Future Foresights of Biologics in Orthopaedic Surgery Field"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "452", "bibliographicPageStart": "449", "bibliographicVolumeNumber": "131", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Rheumatoid arthritis (RA) is chronic and inflammatory autoimmune diseases. Biologics have been treated for refractory RA patients. In our facility, they have been used since 2001 and totally 702 cases by the end of August, 2016. Retention rates of each biologics in our facility were as follows; tocilizumab: 82% (1 year) and 75% (2-years), etanercept: 78% and 71%, infliximab: 70% and 61%, adalimumab: 67% and 54%, and then abatacept, certorizumab pegol, golimumab, in order. The clinical outcome of subcutaneously injected tocilizumab (TCZ-SC) was evaluated. TCZ-SC was administered for 40 patients with RA from 2013 through March 2016. The age was 62 years old on average (range; 24-86), disease duration of RA was 8 years on average (0.08-38 years). Biologics naive cases was 30 cases (75%). Methotrexate was used in 14 cases (35%) and prednisolone was used in 15 cases (38%), respectively. Disease activity score 28 (DAS28) was decreased from 4.72 before induction of TCZ-SC to 2.07 after 3 months, and 1.89 after 12 months. The DAS28 remission rate reached 76% just after 3 months and it was maintained to 81% after 12 months. TCZ-SC was ceased in 5 cases within the observation period. Of these, 4 cases were due to the adverse events and 1 was due to non-efficacy. In conclusion, total management is important for achieving tight control of RA patients by monitoring joint pain, swelling, and deformity with physical status, ultrasonography, or X-ray findings in the clinical settings.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "57733", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Kondo, Naoki"}]}, {"nameIdentifiers": [{"nameIdentifier": "57734", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Fujisawa, Junichi"}]}, {"nameIdentifiers": [{"nameIdentifier": "57735", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Kudo, Naoko"}]}, {"nameIdentifiers": [{"nameIdentifier": "57736", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Murai, Takehiro"}]}, {"nameIdentifiers": [{"nameIdentifier": "57737", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Endo, Naoto"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "近藤, 直樹"}], "nameIdentifiers": [{"nameIdentifier": "57728", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "藤沢, 純一"}], "nameIdentifiers": [{"nameIdentifier": "57729", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "工藤, 尚子"}], "nameIdentifiers": [{"nameIdentifier": "57730", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "村井, 丈寛"}], "nameIdentifiers": [{"nameIdentifier": "57731", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "遠藤, 直人"}], "nameIdentifiers": [{"nameIdentifier": "57732", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-06"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "131(8)_449-452.pdf", "filesize": [{"value": "2.2 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2200000.0, "url": {"label": "131(8)_449-452.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/8221/files/131(8)_449-452.pdf"}, "version_id": "98ce48f8-315e-46c5-b303-663df4468fc5"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "rheumatoid arthritis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "biologics", "subitem_subject_scheme": "Other"}, {"subitem_subject": "retention rate", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tocilizumab", "subitem_subject_scheme": "Other"}, {"subitem_subject": "management for joints", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "1 整形外科領域 (シンポジウム 各科領域における生物学的製剤の現況と展望, 第720回新潟医学会)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "1 整形外科領域 (シンポジウム 各科領域における生物学的製剤の現況と展望, 第720回新潟医学会)"}, {"subitem_title": "1 整形外科領域 (シンポジウム 各科領域における生物学的製剤の現況と展望, 第720回新潟医学会)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "884"], "permalink_uri": "http://hdl.handle.net/10191/49657", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-02-28"}, "publish_date": "2018-02-28", "publish_status": "0", "recid": "8221", "relation": {}, "relation_version_is_last": true, "title": ["1 整形外科領域 (シンポジウム 各科領域における生物学的製剤の現況と展望, 第720回新潟医学会)"], "weko_shared_id": null}
  1. 0 資料タイプ別
  2. 03 紀要論文
  1. 250 大学院医歯学総合研究科(医)
  2. 20 紀要
  3. 02 新潟医学会雑誌
  4. 第131巻第8号

1 整形外科領域 (シンポジウム 各科領域における生物学的製剤の現況と展望, 第720回新潟医学会)

http://hdl.handle.net/10191/49657
http://hdl.handle.net/10191/49657
0d4fd191-cbf7-434e-b032-517ba8081338
名前 / ファイル ライセンス アクション
131(8)_449-452.pdf 131(8)_449-452.pdf (2.2 MB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2018-02-28
タイトル
タイトル 1 整形外科領域 (シンポジウム 各科領域における生物学的製剤の現況と展望, 第720回新潟医学会)
タイトル
言語 en
タイトル 1 整形外科領域 (シンポジウム 各科領域における生物学的製剤の現況と展望, 第720回新潟医学会)
言語
言語 jpn
キーワード
主題Scheme Other
主題 rheumatoid arthritis
キーワード
主題Scheme Other
主題 biologics
キーワード
主題Scheme Other
主題 retention rate
キーワード
主題Scheme Other
主題 tocilizumab
キーワード
主題Scheme Other
主題 management for joints
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
その他のタイトル
その他のタイトル Current Trends and Future Foresights of Biologics in Orthopaedic Surgery Field
著者 近藤, 直樹

× 近藤, 直樹

WEKO 57728

近藤, 直樹

Search repository
藤沢, 純一

× 藤沢, 純一

WEKO 57729

藤沢, 純一

Search repository
工藤, 尚子

× 工藤, 尚子

WEKO 57730

工藤, 尚子

Search repository
村井, 丈寛

× 村井, 丈寛

WEKO 57731

村井, 丈寛

Search repository
遠藤, 直人

× 遠藤, 直人

WEKO 57732

遠藤, 直人

Search repository
著者別名
識別子 57733
識別子Scheme WEKO
姓名 Kondo, Naoki
著者別名
識別子 57734
識別子Scheme WEKO
姓名 Fujisawa, Junichi
著者別名
識別子 57735
識別子Scheme WEKO
姓名 Kudo, Naoko
著者別名
識別子 57736
識別子Scheme WEKO
姓名 Murai, Takehiro
著者別名
識別子 57737
識別子Scheme WEKO
姓名 Endo, Naoto
抄録
内容記述タイプ Abstract
内容記述 Rheumatoid arthritis (RA) is chronic and inflammatory autoimmune diseases. Biologics have been treated for refractory RA patients. In our facility, they have been used since 2001 and totally 702 cases by the end of August, 2016. Retention rates of each biologics in our facility were as follows; tocilizumab: 82% (1 year) and 75% (2-years), etanercept: 78% and 71%, infliximab: 70% and 61%, adalimumab: 67% and 54%, and then abatacept, certorizumab pegol, golimumab, in order. The clinical outcome of subcutaneously injected tocilizumab (TCZ-SC) was evaluated. TCZ-SC was administered for 40 patients with RA from 2013 through March 2016. The age was 62 years old on average (range; 24-86), disease duration of RA was 8 years on average (0.08-38 years). Biologics naive cases was 30 cases (75%). Methotrexate was used in 14 cases (35%) and prednisolone was used in 15 cases (38%), respectively. Disease activity score 28 (DAS28) was decreased from 4.72 before induction of TCZ-SC to 2.07 after 3 months, and 1.89 after 12 months. The DAS28 remission rate reached 76% just after 3 months and it was maintained to 81% after 12 months. TCZ-SC was ceased in 5 cases within the observation period. Of these, 4 cases were due to the adverse events and 1 was due to non-efficacy. In conclusion, total management is important for achieving tight control of RA patients by monitoring joint pain, swelling, and deformity with physical status, ultrasonography, or X-ray findings in the clinical settings.
書誌情報 新潟医学会雑誌
en : 新潟医学会雑誌

巻 131, 号 8, p. 449-452, 発行日 2017-08
出版者
出版者 新潟医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 00290440
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AN00182415
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 18:49:51.678330
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3